EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia -Company expects to initiate Phase 2 study in 2H 2025-San ... eumentis2025-07-30T07:10:24-07:00 Read More